Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
2020 · Annals of Oncology · 137 citations
https://doi.org/10.1016/j.annonc.2020.05.031
T
Tatsuya Takenouchi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
143
Papers
2.6K
Citations
26
h-index
47
i10-index
Tatsuya Takenouchi is an academic researcher from Niigata Cancer Center Hospital. The author has contributed to research in topics: Cutaneous Melanoma Detection and Management & Nonmelanoma Skin Cancer Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 26, co-authored 122 publications.
ORCID: 0000-0002-6818-944XPapers by this author
worksPhase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
2017 · Cancer Chemotherapy and Pharmacology · 86 citations
https://doi.org/10.1007/s00280-016-3237-x
Factors Influencing the Linear Depth of Invasion of Primary Basal Cell Carcinoma
2001 · Dermatologic Surgery · 40 citations
https://doi.org/10.1046/j.1524-4725.2001.27401.x
Key points in dermoscopic diagnosis of basal cell carcinoma and seborrheic keratosis in Japanese
2010 · The Journal of Dermatology · 39 citations
https://doi.org/10.1111/j.1346-8138.2010.01093.x
Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
2022 · European Journal of Cancer · 39 citations
https://doi.org/10.1016/j.ejca.2022.08.030
Long‐term prognosis after surgical excision of basal cell carcinoma: A single institutional study in <scp>J</scp>apan
2013 · The Journal of Dermatology · 36 citations
https://doi.org/10.1111/1346-8138.12207
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat